These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 28625271)
41. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. Rudick CP; Cornell DL; Agrawal DK Expert Rev Clin Immunol; 2017 Sep; 13(9):907-919. PubMed ID: 28742984 [TBL] [Abstract][Full Text] [Related]
42. Sepsis: time has come to focus on the later stages. Schefold JC; Hasper D; Volk HD; Reinke P Med Hypotheses; 2008 Aug; 71(2):203-8. PubMed ID: 18448264 [TBL] [Abstract][Full Text] [Related]
43. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Ayala A; Chaudry IH Shock; 1996; 6 Suppl 1():S27-38. PubMed ID: 8828095 [TBL] [Abstract][Full Text] [Related]
44. Elevated nucleosome levels in systemic inflammation and sepsis. Zeerleder S; Zwart B; Wuillemin WA; Aarden LA; Groeneveld AB; Caliezi C; van Nieuwenhuijze AE; van Mierlo GJ; Eerenberg AJ; Lämmle B; Hack CE Crit Care Med; 2003 Jul; 31(7):1947-51. PubMed ID: 12847387 [TBL] [Abstract][Full Text] [Related]
45. Contribution of programmed cell death receptor (PD)-1 to Kupffer cell dysfunction in murine polymicrobial sepsis. Wang F; Huang X; Chung CS; Chen Y; Hutchins NA; Ayala A Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G237-45. PubMed ID: 27288425 [TBL] [Abstract][Full Text] [Related]
46. [Pathogenesis of sepsis-induced myocardial dysfunction]. Lou Y; Lin Z Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Apr; 30(4):374-376. PubMed ID: 29664003 [TBL] [Abstract][Full Text] [Related]
47. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Monneret G; Venet F Cytometry B Clin Cytom; 2016 Jul; 90(4):376-86. PubMed ID: 26130241 [TBL] [Abstract][Full Text] [Related]
48. Post-infectious immune suppression: a new paradigm of severe infections. Grimaldi D; Llitjos JF; Pène F Med Mal Infect; 2014 Oct; 44(10):455-63. PubMed ID: 25169939 [TBL] [Abstract][Full Text] [Related]
49. The immune system's role in sepsis progression, resolution, and long-term outcome. Delano MJ; Ward PA Immunol Rev; 2016 Nov; 274(1):330-353. PubMed ID: 27782333 [TBL] [Abstract][Full Text] [Related]
50. Recent Advances in the Molecular Mechanisms Underlying Pyroptosis in Sepsis. Gao YL; Zhai JH; Chai YF Mediators Inflamm; 2018; 2018():5823823. PubMed ID: 29706799 [TBL] [Abstract][Full Text] [Related]
51. What is next in sepsis: current trials in sepsis. Artigas A; Niederman MS; Torres A; Carlet J Expert Rev Anti Infect Ther; 2012 Aug; 10(8):859-62. PubMed ID: 23030324 [TBL] [Abstract][Full Text] [Related]
52. The growing spectrum of anti-inflammatory interleukins and their potential roles in the development of sepsis. Zhao HQ; Li WM; Lu ZQ; Sheng ZY; Yao YM J Interferon Cytokine Res; 2015 Apr; 35(4):242-51. PubMed ID: 25517926 [TBL] [Abstract][Full Text] [Related]
53. Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression. Yao RQ; Ren C; Zheng LY; Xia ZF; Yao YM Front Immunol; 2022; 13():891024. PubMed ID: 35619710 [TBL] [Abstract][Full Text] [Related]
54. [Sepsis in Emergency Medicine]. Christ M; Geier F; Bertsch T; Singler K Dtsch Med Wochenschr; 2016 Jul; 141(15):1074-81. PubMed ID: 27464279 [TBL] [Abstract][Full Text] [Related]